The ZAPI project was launched in response to topic 4 of the 11th call of the Innovative Medicines Initiative (IMI). On May 6th 2015 the kick-off meeting of ZAPI was held at Schiphol airport.
ZAPI aims to shorten the time to adequately respond to emerging infectious diseases using a One Health approach. The project will yield platforms for the rapid identification and production of viral domains that can be used as veterinary vaccines and will yield platforms for the rapid development, selection and production of protective antibodies to protect the human population. The project will not only aim at rapid development of these products, but also ensure fast track registration and implementation of the control tools as soon as possible after pathogen emergence.
To develop these pipelines, the project will focus on three priority pathogens:
- Rift Valley fever virus (RVFV)
- Schmallenberg virus (SBV)
- Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Specific major aims of ZAPI:
- Platforms that are suitable for rapid surge production of vaccines
- Platforms that allow the rapid identification and production of antibodies capable of neutralizing emerging viruses
- Development of release assays that do not make use of animals
- Development of protocols for fast-track registration of developed products
The project brings together 20 European partners from academia, industry and regulatory specialists with a budget of over 20 m€ and will have a duration of 5 years.
- Erasmus Medical Center (EMC)
- Utrecht University (UU)
- Central Veterinary Institute (CVI)
- Friedrick-Loeffler Institute (FLI)
- University of Bonn (UKB)
- Viroclinics Biosciences B.V.
- Centro Nacional de Biotecnologia (CNB CSIC)
- Pasteur Institute
- Aix-Marseille University (AMU)
- Artemis B.V. (Artemis)
- Centre de Recerca en Sanitat Animal (CReSA)
- University of Hannover (TiHo)
- International Alliance for Biological Standardization (IABS-EU)
- Leiden University Medical Center (LUMC)
- Boehringer Ingelheim Veterinary Research Center GmbH & Co. KG (BIVRC)
- Dyadic Nederland BV
- MedImmune-AstraZeneca (AZ)
- Harbour Antibodies B.V.